Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?Cristiana Sessa, Curzio Rüegg, Aymeric Guibal et al.|Nature Clinical Practice Oncology|2008Cited by 148
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursGianluca Del Conte, Luca Gianni|British Journal of Cancer|2014Cited by 103
Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.Angelica Fasolo, Luca Gianni, J Bauer et al.|Journal of Clinical Oncology|2010Cited by 1
Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors.C. Sessa, Luca Gianni, Elisa Gallerani et al.|Journal of Clinical Oncology|2011Cited by 0